Source:http://linkedlifedata.com/resource/pubmed/id/19212683
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2009-2-12
|
| pubmed:abstractText |
Anemia is a unique side effect in Korean gastric cancer patients after S-1 monotherapy. We studied gastric cancer patients from a phase II trial of S-1 monotherapy with a 2-week treatment and 1-week rest schedule. Patients from a phase II trial of S-1 monotherapy with a 4-week treatment and 2-week rest were used as a reference group. The patients were categorized into two groups based on the degree of hemoglobin reduction per cycle of S-1: the mild reduction group (MRG DeltaHb/cycle < or =1.0) or severe reduction group (SRG DeltaHb/cycle >1.0). DeltaHb/cycle was calculated from maximum reduction of hemoglobin per one cycle of the treatment. Microarray-CGH was performed using a 17K cDNA microarray containing 15,723 unique genes. We selected genes with copy number variation defined as amplification (log2R/G >0.68) or deletion (log2R/G <-0.68), and a genetic aberration frequency difference of > or =30% between the MRG and the SRG. There were no differences in clinical factors, S-1 treatment-related factors (dose, dose intensity), toxicity, S-1 metabolism-related gene copy numbers (CYP2A6, DPD), or progression-free survival between the MRG and the SRG. Three genes were selected from microarray-CGH and logistic regression model: logit LN(Z) = (1.321) + (1.038 x PTX1) + (0.211 x MYO5A) + (0.516 x ZNF664). In the SRG, all 3 genes showed a trend of higher copy numbers than the MRG. There were no common anemia-related genes identified from different chemotherapy schedule of S-1 monotherapy. The logistics obtained from 3 genes predicted the hemoglobin reduction with an accuracy of 78%. The AUC was 0.744 for the final regression model. The combined copy number changes of the 3 genes can be developed into a biomarker in predicting S-1 treatment-related anemia.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobins,
http://linkedlifedata.com/resource/pubmed/chemical/Oxonic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/S 1 (combination),
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1019-6439
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
34
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
787-96
|
| pubmed:meshHeading |
pubmed-meshheading:19212683-Adult,
pubmed-meshheading:19212683-Aged,
pubmed-meshheading:19212683-Anemia,
pubmed-meshheading:19212683-Antimetabolites, Antineoplastic,
pubmed-meshheading:19212683-Disease-Free Survival,
pubmed-meshheading:19212683-Dose-Response Relationship, Drug,
pubmed-meshheading:19212683-Drug Administration Schedule,
pubmed-meshheading:19212683-Drug Combinations,
pubmed-meshheading:19212683-Female,
pubmed-meshheading:19212683-Gene Dosage,
pubmed-meshheading:19212683-Hemoglobins,
pubmed-meshheading:19212683-Humans,
pubmed-meshheading:19212683-Male,
pubmed-meshheading:19212683-Middle Aged,
pubmed-meshheading:19212683-Oxonic Acid,
pubmed-meshheading:19212683-Stomach Neoplasms,
pubmed-meshheading:19212683-Survival Rate,
pubmed-meshheading:19212683-Tegafur,
pubmed-meshheading:19212683-Treatment Outcome
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer.
|
| pubmed:affiliation |
Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seodaemun-Ku, Seoul 120-752, Korea.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|